AACR22: natural killer cells show promise as a possible lymphoma treatment

Results from a Phase I/II trial have demonstrated that natural killer (NK) cells derived from cord blood, which were activated and complexed with a CD30/CD16A bispecific antibody, elicited a 89% overall response rate in patients with relapsed or refractory CD30+ lymphoma. The findings were recently presented at the AACR 2022 Annual Meeting (8−13 April 2022; LA, USA). CD30 is a receptor that is expressed on certain cells in multiple forms of Hodgkin’s lymphoma, and some forms of non-Hodgkin's lymphoma. When CD30 is activated, it encourages the growth of cancer cells. Currently, the standard of care for relapsed CD30+ lymphomas is...